StemCell Therapy

Global Nucleic Acid Isolation and Purification Market to Reach $3,835.2 Million by 2029

NEW YORK, April 9, 2020 /PRNewswire/ --

Read the full report: https://www.reportlinker.com/p05881508/?utm_source=PRN

Key Questions Answered in this Report: What are the major market drivers, challenges, and opportunities in the global nucleic acid isolation and purification market? What are the key development strategies which are being implemented by major players in order to sustain in the competitive market? How each segment of the market is expected to grow during the forecast period from 2020 to 2029 based on o product type: instrument and consumables (kits and reagents) o end User: academic research institutes, pharmaceutical and biotechnology companies, applied testing, contract research organizations, and clinical diagnostic centers o region, North America, EMEA, Asia-Pacific, and Latin America Which are the leading players with significant offerings to the global nucleic acid isolation and purification market? What is the expected market dominance for each of these leading players? Which companies are anticipated to be highly disruptive in the future and why? What are the challenges in the nucleic acid isolation and purification market?

Global Nucleic Acid Isolation and Purification Market Forecast, 2020-2029

The nucleic acid isolation and purification industry analysis projects the market to grow at a significant CAGR of 5.98% during the forecast period, 2020-2029. The nucleic acid isolation and purification market generated $2,273.9 million revenue in 2020, in terms of value. The nucleic acid isolation and purification market growth has been primarily attributed to the major drivers in this market, such as growing number of genetic tests, increasing demand for reliable next-generation sequencing (NGS) results, rise in the prevalence of infectious diseases, increasing research funding in the field of molecular biology, and increase in awareness and acceptance of personalized medicine on a global level. However, genomic data protection, high cost of automated instruments, and rigid regulatory standards are some of the factors expected to retrain the market growth.

Expert Quote

"As molecular diagnostic testing moves into the clinical laboratory environment, products used to collect and process samples will need to be standardized"

Scope of the Market Intelligence on Nucleic Acid Isolation and Purification Market

The nucleic acid isolation and purification research provides a holistic view of the market in terms of various factors influencing it, including regulatory reforms, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers. In addition, the study also includes exhaustive information on the drivers, restraints opportunities, perception of the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global nucleic acid isolation and purification market.

Market Segmentation

The nucleic acid isolation and purification market (on the basis of product type) is segmented into instruments and consumables (kits and reagents).

The kits segment (on the basis of technology) has been classified into magnetic particle technology, silica technology, and other technologies. The other technologies have been broadly bifurcated into anion-exchange technology, lysis, precipitation-based chemistries, organic extraction, fluorescence, and other kits technologies.

Further, the instruments (on the basis of technology) has been classified into automated spin-column based and bead-based. The bead-based technology has been further bifurcated into magnetic bead-based and automated liquid handling.

The nucleic acid isolation and purification market (on the basis of applications) is segmented into PCR, qPCR, NGS, cloning, microarray, blotting techniques, and other applications.

The nucleic acid isolation and purification market (on the basis of end-user) is segmented into academic research institutes, pharmaceutical and biotechnology companies, applied testing, biobanks, contract research organizations, hospital research laboratories, and clinical diagnostic centers.

The nucleic acid isolation and purification market (on the basis of region) is segmented into North America, EMEA, Asia-Pacific, and Latin America.

Key Companies in the Nucleic Acid Isolation and Purification Market

The key manufacturers who have been contributing significantly to the nucleic acid isolation and purification market are Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F.Hoffmann-La Roche AG, Illumina, Inc., General Electric Company (GE), New England Biolabs, Inc., Promega Corporation, Merck KGaA, Takara Bio Inc., QIAGEN N.N., Thermo Fisher Scientific Inc., and Promega Corporation, among others.

Countries Covered North America U.S. Canada Europe, Middle East & Africa (EMEA) Latin America (LATAM) Asia-Pacific China Japan Rest-of-APAC

Read the full report: https://www.reportlinker.com/p05881508/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Story continues

View original content:http://www.prnewswire.com/news-releases/the-nucleic-acid-isolation-and-purification-industry-analysis-by-bis-research-projects-the-market-to-grow-at-a-significant-cagr-of-5-98-during-the-forecast-period-2020-2029--301038446.html

SOURCE Reportlinker

Read the original post:
The nucleic acid isolation and purification industry analysis by BIS Research projects the market to grow at a significant CAGR of 5.98% during the...

Theres nothing better as an investor than owning shares of companies that improve our lives. At the top of that list is companies that help us live healthier, longer lives.

Source: Shutterstock

Back in November which seems like an eternity ago I wrote that 2020 would be the Year of Biotech. Neither I nor anyone else knew how critical medical sciences and healthcare would become just a few months later amid a worldwide pandemic.

I still see 2020 as the Year of Biotech.

These stocks have shown relative strength in the bear market, and the current crisis gives us a glimpse of the innovative breakthroughs coming our way including efforts to fight the coronavirus.

In a volatile stock market like this, you can buy most stocks at a massive discount. Big names are down 20% 30% even 50%. Some small-cap stocks have slid even more.

This rare situation has opened up an unusual buying opportunity that we havent seen for at least the past decade or longer.

Fundamentally, the investment mega-trends Im following including in my new Crisis and Opportunity Portfolio are still on track. The coronavirus has scrambled everyones plans for the moment, but it wont last. The market has recovered from every past bear market, and were seeing glimmers of hope in the number of new cases around the world.

Ive been saying for more than week now that its time to start investing in stocks again. Believe me, trying to pick an exact bottom isnt worth the risk. Instead, you have to focus on the trends that will spawn the markets next big winners.

Biotechnology is one of these unstoppable mega-trends.

In 2019, before the coronavirus was on anyones mind, investors poured $13.9 billion into biotech startups. That was $4 billion less than 2018s record-breaking number but still higher than any other year on record.

The industry was climbing to new heights as companies began using next-generation technologies like artificial intelligence (AI) to find new drugs for diseases like cancer quicker and cheaper than ever before.

Another cutting-edge technology thats been on the rise is genomics, which will usher in a new era of personalized medicine for each patient as well as speed up the creation of new drugs.

And at this particular moment, it makes sense that investors would take notice as biotechs around the world are on high alert to find better drugs and/or a vaccine to tame the coronavirus.

Indeed, the sector has held steady through the recent volatility. Its one of the broader markets top performers.

So far this year, the S&P 500 is down more than 17% while theVanEck Vectors Biotech ETF (NASDAQ:BBH) is down closer to 5.6%. Thats far better than some of the other sectors that you might think would be strong right now like household products and food and staples retailing, which are both down 15%, according to Fidelity.

Yes, many biotech stocks are down at the moment. But that sets up an incredible chance to get some of the best at a discount.

Right now, more than 140 experimental coronavirus treatments and vaccines are in the works worldwide, according to theWall Street Journal. Researchers are moving at record pace, setting up 254 clinical trials to test drugs and/or vaccines in a matter of weeks or days.

Whether a given company is a part of this effort or not, nearly every biotech has been impacted by the pandemic. For instance, clinical trials are getting pushed back while healthcare facilities around the globe have shut down for fear of spreading the virus.

But the delay is short term. And longtimeMoneyWirereaders know that we focus on the long-term big picture.

Artificial intelligence and genomics already play a key role in the biotech industry as companies try to find a workable solution for whats ailing all of us.

And unlike the recent focus on producing protective equipment and coronavirus tests that will likely fizzle after the worst has passed,the use of these technologies will only continue to grow.

My #1 stock in theCrisis and Opportunity Portfoliothat I just released last week is a great example. The company uses AI in its predictive analytics to improve patient care and lower costs for insurance companies. Part of that involves the exploding trend of telehealth.

Telehealth includes the virtual doctors visits that are keeping us all out of waiting rooms during the pandemic. But I suspect doctors and patients alike will stick with the convenience and efficiency of the service long after the current crisis passes.

This stock lost a lot of ground in the sell-off, but it is already up 33% since I recommended it last Wednesday. The company is forecast to deliver 61% annual revenue growth and has a clear path to profitability, which is important when investing in smaller companies. I see a lot more upside to come.

Finding the best small companies in the best industries like biotech that will see the biggest gains as we recover is what my newCrisis and Opportunity Portfoliois all about.

Ive handpicked the companies best positioned to soar, and were adding them strategically one by one. Thats the smartest way to buy in this still-volatile market.

The current selling is setting up amazing buying opportunities in investment trends that wont slow due to the pandemic. The key is knowingwhich ones represent the best potential over the long term.

Matthew McCall left Wall Street to actually help investors by getting them into the worlds biggest, most revolutionary trends BEFORE anyone else. The power of being first gave Matts readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA) and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now.Matt does not directly own the aforementioned securities.

Original post:
Biotech Stocks: Big Buying Opportunities in 2020s Sector of the Year - Investorplace.com

SOUTH PLAINFIELD, N.J., April 6, 2020 /PRNewswire/ -- Accurate Diagnostic Laboratories (ADL) and Rutgers University Cell & DNA Repository (RUCDR), through its Clinical Genomics Laboratory, are pleased to announce a joint mission aligning their efforts around improving testing capacity and service for the hospital inpatient population, health care providers and workers, first responders and patients.The relationship will facilitate providing high through-put and industry-leading turn around time for COVID-19 testing, also capitalizing on new methods to test. ADL and RUCDR have a long-standing relationship, where ADL performs diagnostic testing for RUCDR clinical trials, which aides in their data repository management. RUCDR, in conjunction with ADL's clinical client-base, fast-tracked the validation and verification of new testing methodologies, including saliva, for SARS-CoV-2 COVID-19. These alternate collection options will catapult the access of testing and screening to our most needed population."ADL's laboratory diagnostic capabilities, steeped in a tradition of offering the latest diagnostic technology offerings, is proud to expand our relationship with a local, world-renowned institution in Rutgers University Cell & DNA Repository laboratory.We want to do our mutual part to address the need for improved COVID-19 testing access, particularly for our front-line health care workers, hospital inpatient population, and first responders, by utilizing new collection and testing methods," says ADL's CEO, Rupen Patel.This is a game-changer for the market as "saliva testing will help with the global shortage of swabs for sampling and increase testing of patients, as it will not require health care professionals to collect samples," said Dr. Andrew Brooks, COO and director of technology development at RUCDR Infinite Biologics.He is also a professor in the Department of Genetics at Rutgers University-New Brunswick.As far as we know, we are the first and only laboratory to perform a significant validation and verification on multiple specimen types and not rely solely on the use of contrived samples.Accurate Diagnostic would like to formally thank those health care providers and health systems that assisted in the process to get this testing off the ground.

About Accurate Diagnostic Labs: Accurate Diagnostic Labs is one of the largest privately held, boutique, full-service clinical laboratories in the country.ADL, as a full-service core laboratory, proudly works with various entities on laboratory testing for clinical trial drug development and data repository in various market footprints to progress the field of disease state management and personalized medicine. With our local headquarters based in Central New Jersey, we pride ourselves in working with various healthcare corporations, institutions, health systems, and the local providers in the metropolitan area with the common goal of improving local and national healthcare.

Contact Information for ADL: For more information on ADL, please call at 732-839-3300 or visit online at http://www.accuratediagnosticlabs.com.

About RUCDR:RUCDR Infinite Biologics, which is part of Rutgers'Human Genetics Institute of New Jersey, is the world's largest university-based cell and DNA repository. Its mission is to understand the genetic causes of common, complex diseases and to discover diagnoses, treatments and cures for them. The organization collaborates with researchers in the public and private sectors throughout the world, providing the highest quality bio-banking services and biomaterials, as well as scientific and technical support.

Related Files

RUCDR ADL press release.docx

Related Images

rucdr.pngRUCDR

adl.pngADL

More:
Accurate Diagnostic Laboratories and Rutgers University Cell & DNA Repository Lab Work Together to Change the COVID-19 Testing Landscape - WFMZ...

Recently, as I was scheduling a routine procedure, the nurse asked for my fax number so she could send me the pre-op procedures. A fax machine in todays age? I was flabbergasted, as this was from an affiliate of one of the most sophisticated medical institutions in the United States, if not the world. I asked her to send me an email, and she indicated her systems were not equipped to do that but she might be able to scan the instructions and email them to me.

In light of the sweeping spread of Covid-19 and the increased pressure that has been and will continue to be brought to bear on the healthcare system, my experience becomes almost chilling.

As Cynthia Cox, director of the Peterson-Kaiser Health System Tracker recently commented to Vox: The coronavirus outbreak is already exposing inefficiencies and inequities in our health system, and it is likely to put much more strain on the system in the coming weeks.

And yet, we shouldnt need a pandemic to inform us that we need to bring our healthcare administration practices into modernity or to show investors the opportunity they have to bring about much-needed change.

My fax experience indicates that one major area to address is the antiquity of our healthcare system. In a time when our leaders and healthcare providers now face real concerns about Covid-19s potential to overwhelm our facilities and drain our resources, we have to wonder could the application of modern technology have improved our ability to handle a pandemic? The answer seems surely to be yes.

It is mind-boggling how healthcare practices stand in stark contrast to how advances in technology and science have dramatically improved diagnosing and treating a host of issues. In this context, profiting as an investor doesnt require one to be steeped in science or healthcare. In fact, one might argue that its best to come from the outside and apply a fresh perspective, as has been the case with many recent healthcare-focused entrepreneurs.

The marketplace for healthcare is massive; it literally applies to everyone. In the US alone, healthcare represents over $3 trillion or 18% of GDP. Its perplexing how an industry so large and all-consuming could be forced to rely on something as outdated as the fax machine.

The size, growth and dysfunction in healthcare lead me to believe there are few investment environments as fruitful as those concentrating on improving many key aspects of healthcare. There are enormous opportunities in biotechnology that are now possible due to massive leaps in computing power and cost, but I believe there are also equal opportunities to improve the actual processes associated with delivering healthcare. In the latter category, one is not required to have a deep science or medical aptitude to pursue or capitalize on.

It is these areas that I am most excited about, as they present the possibilities of applying otherwise-available technology to improving quality and reducing costs. According to Harry Glorikian in Moneyball Medicine, There are also substantial wastes and inefficiencies in healthcare factors that could be costing the United States $1 trillion. This includes costs related to overtreatment and unnecessary treatments, bloated administrative structures, fraud and overspending that result from an inability to effectively shop for best price. These gaps, failings and their corresponding enormities are an entrepreneurs and investors dream.

At its core, medicine is about gathering, deciphering and sharing information; information flows between patients and doctors, doctors and doctors, doctors and pharmacists, and so forth. This stream of facts, figures, and experiences ultimately results in the care of a patient.

Thanks to the transformative technologies weve seen in this young century, a transformation in the processing and dissemination of information has taken place, with more knowledge at our fingertips than imaginable just a few decades ago. From globe-spanning social connections to seemingly infinite encyclopedias to mobile connectivity and computing, several quantum leaps forward in technological capabilities now enable forward-thinkers to create a new world where price transparency and seamless collaboration are the norm.

Yet, despite the enormous advances in processing power and capability over the last 50 to 100 years, there remain many aspects of the actual process of practicing medicine that have barely evolved. While machines are unlikely to completely replace doctors anytime soon (or ever), the fact remains that there are a number of areas where the accurate, timely processing of information can dramatically improve patient well-being and ultimately the quality, cost and accessibility of both basic and complex healthcare.

Areas, like streamlining administrative processes, reducing redundancy or unnecessary procedures, or facilitating early and frequent interaction with medical professionals to treat conditions early or prevent them in the first place, are ripe for disruption from innovative approaches driven by technology. Investments in the following four categories are among the most obvious, lucrative and mutually advantageous areas where transformational change is possible and needed.

Medical Records: When you think about it, health records are actually incredibly inefficient. Not only do you have to fill out comprehensive medical questionnaires by handyou have to repeat this process every time you change doctors, switch insurance companies, or alter your records in any way. Not only is this a colossal waste of time, but I shudder to think of the details that are mistaken or forgotten and how that might impact optimal care.

Its not unreasonable to expect that, in todays digital age, ones health records should not only be easily accessible but also reside with the individual rather than being dispersed among the countless healthcare providers that the person is involved with. For too long, healthcare providers have been overly protective of this information often to the detriment of the patient. While some strides have been made in this area, substantial work remains to be done to create true interoperability among providers for a specific patient.

This efficiency will improve the process of caring for a patient and in many cases will improve outcomes because doctors will always instantly have comprehensive information at their fingertips. Medical histories, treatment plans or idiosyncratic issues will no longer slip through the cracks. The scope of this issue is highlighted when considering patients dealing with multiple complex issues that might involve numerous specialists and general practitioners. Moreover, a patients health record shouldnt be just for the provider, it should be user-friendly so that the patients themselves can monitor and manage their health.

Big players in tech are already making strides towards filling this customer service void, but the big gamechanger in this field still has yet to present itself. Its a completely realistic expectation that within the next decade well have moved onto quick, convenient, and secure medical records. There likely will be many players enabling the gathering, managing and sharing of patient information; however, the real transformational change will occur when the data contained in the health record is used to proactively diagnose and treat patients.

The Delivery of Care: Traditionally, the doctors office or hospitals was where medicine was almost exclusively practiced. Today, technology is enabling care for many basic issues to be delivered remotely to wherever the patient is. Telemedicine, or virtual care, utilizes technology so that doctors can seamlessly and, in some cases, instantly connect with patients to deliver care on demand.

The first iteration of this approach is traditional telemedicine, which uses video conferencing or a phone call to connect a doctor and patient. This approach is quickly and not unsurprisingly being usurped by asynchronous text on a smartphone how the world prefers to communicate where the doctors capabilities are being augmented by deep technology and AI. Providing easy and true on-demand accessibility for patients enables them to be treated early and often, which will unquestionably improve health outcomes. Pairing physicians with leading-edge technology can generate substantial efficiencies and leverage that, in turn, will reduce costs, increase quality and substantially expand those covered.

The flu offers a simple illustration of the power of technology that allows on-demand, remote care delivery: At the onset of symptoms, a patient can engage with a doctor and receive treatment. Instead of juggling their schedules or waiting to see a doctor which averages 29 days according to a Merritt Hawkins 2017 study the disease is treated promptly before it gets too far along. Furthermore, this remote treatment dramatically reduces contamination because there is no sitting in a waiting room or traveling often on mass transit to visit a doctor or urgent care center. In this scenario, everyone patient, provider, community and employer wins.

Similarly, technology is transforming how a patient is monitored either following a procedure or for chronic issues. In many cases, vital statistics can be monitored remotely and transmitted instantly to a care team. This enables patients to recover at home, which is more comfortable, cheaper, and comes without the infectious risks present at a hospital. For patients with chronic diseases, the ability to easily and accurately monitor factors like blood glucose levels, heart rate or blood pressure can be transformative in terms of managing a disease or preventing problems down the road. On a related note, technology-based tools can be employed to aid and ensure prescription adherence, which currently poses a huge and unnecessary cost to the system.

Healthcare delivery is only beginning to embrace the power of technology especially that of a smartphone to cut costs, increase access and improve quality. As I previously wrote, I believe that the power and ubiquity of smartphones will improve the worlds health on an individual and collective basis. Virtually every other aspect of our lives have been enhanced by this technology with the exception of primary healthcare.

Clinical Decision Support: The capabilities of AI, machine learning and big data can be applied to many aspects of healthcare in order to leverage a doctors time, improve quality and drive much needed efficiencies. Deep technology can now review images and tests faster and often more accurately than humans. The sheer mass and dispersion of medical information and current research makes it virtually impossible for a single doctor to always be up to speed. Technology that can foster the analysis and sharing of vast and complicated information will give doctors instant access to the plethora of research studies and clinical trials that might be relevant to their patients. Using technology to quickly and accurately identify and process information on a clients behalf will only improve care and drive down costs.

Precision Medicine / Personalized Diagnoses: Given the powerful computers at our disposal, it is easy to envision how we could use computers to aid decision-making, plugging in numerous permutations, conditions, and individual attributes unique to patients in order to determine the problems at hand and the optimal treatment plan. For example, for a prescription one will no longer need to rely on the catch all adult dosage and can instead determine the best amount for each patient based on their unique composition and metabolism.

Personalizing diagnoses is where AI is beginning to show real promise. Researchers have developed the technology for identifying heart disease, lung cancer and eye maladies with machine learning, and theyre only getting started. Even more cutting-edge is where a patients genome is analyzed to determine precisely the diagnosis and corresponding treatment plan. This capability is still in its infancy and only possible due to the advancements and price reductions in computing power.

Healthcare is ripe for the benefits technology affords and, as the responses and capabilities relating to Covid-19 demonstrates, desperately needs an update. Relative to other areas, I think the aforementioned categories might be low hanging fruit and hence represent significant investment potential. What I find particularly exciting is that the space is so large and in such desperate need that there will be a wide array of places to invest with potentially several players in each area. Fields such as Artificial Intelligence, Data Management and Cloud Computing offer much promise when applied to healthcare, especially in disrupting several areas that suffer from stagnation and lack of development. These applications will benefit doctors and patients alike while concurrently offering very attractive returns to the investors and entrepreneurs behind the companies. Lastly, and equally compelling, is that an investment that helps improve healthcare provides a greater good by enhancing lives and benefiting communities.

Photo: JamesBrey, Getty Images

Go here to see the original:
Is there a better market to invest in than healthcare? - MedCity News

DUBLIN, April 6, 2020 /PRNewswire/ -- The "Global Minimally Invasive Biopsy Technologies Market: Focus on Liquid Biopsy, Optical Biopsy, and Brush Biopsy, Pigmented Lesion Assays, and Breath Biopsy, Regulatory Scenario, Therapeutic Application, Competitive Landscape,18 Countries' Data - Analysis and Forecast, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

According to the report, the global minimally invasive biopsy technologies market was valued at $924.8 million in 2018 and is anticipated to reach $4.03 billion by 2030. The global minimally invasive biopsy technologies market is expected to grow at a double-digit compound annual growth rate (CAGR) in the forecast period 2019-2030, aided primarily by the anticipated launch of novel minimally invasive biopsy technologies.

The rapidly growing incidences of cancer and other chronic inflammatory disorders are inciting the use of minimally invasive and real-time diagnostic methods for early detection. With better patient compliance and greater sensitivity, minimally invasive biopsy technologies such as liquid biopsy and optical biopsy are emerging as novel tools for the early detection and effective disease management. Additionally, several other technologies including brush biopsy, fine needle aspiration, breath biopsy, and pigmented lesion assays are considerably evolving to be used in the minimally invasive management of cancer.

The increasing adoption of targeted therapies and the growing prominence of the concept of personalized medicine is driving the adoption of minimally invasive biopsy technologies. The increasing adoption is further expected to bring down the cost and is expected to improve the patient access to these technologies.

North America is the leading contributor in the global minimally invasive biopsy technologies market and contributed approximately 62.06% to the global market value in 2018. This region is anticipated to grow at a CAGR of 11.25% during the forecast period 2019-2030 and to continue dominating the global market in 2030 as well. However, the European region is expected to grow at an impressive CAGR of 15.40% during the forecast period 2019-2030. The Asia-Pacific region contributed a share of 12.41% to the global market and is anticipated to grow at a CAGR of 14.65% during the forecast period 2019-2030.

Research Highlights

Optical biopsy expected to witness an impressive CAGR of 15.77% during the forecast period 2019-2030. Moreover, in terms of therapeutic application, prostate cancer is expected to witness an impressive growth at a CAGR of 14.97% during the forecast period 2019-2030.

Liquid biopsy is currently the largest shareholder in the global minimally invasive biopsy technologies market. This market dominance is largely attributed to the worldwide availability of a significant number of liquid biopsy technologies.

This market intelligence report provides a multi-dimensional view of the global minimally invasive biopsy technologies market in terms of market size and growth potential. This research report aims at answering various aspects of the global minimally invasive biopsy technologies market with the help of key factors driving the market, restraints that can possibly inhibit the overall growth of the market, and the current growth opportunities that are going to shape the future trajectory of the market expansion.

Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with the recent market activities, such as product launches and approvals, partnerships, collaborations, business expansions, as well as mergers and acquisitions. The research report provides a comprehensive analysis of the product sales, manufacturers, service providers, and trend analysis by segment, and growth share analysis by region. Additionally, the report provides a comprehensive attractive analysis and opportunity analysis for the entire global minimally invasive biopsy technologies market for 2018 and 2030.

This report is a meticulous compilation of the research of about 65 players in the market ecosystem and draws upon insights from in-depth interviews with the key opinion leaders of 9 leading companies, market participants, and vendors. The report also comprises 15 detailed company profiles including that of Abcodia Ltd., Adaptive Biotechnologies, Biocept, Inc., Caliber Imaging & Diagnostics, Chronix Biomedical, DermTech, F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Mauna Kea Technologies, Myriad Genetics, NeoGenomics Laboratories, Inc., Owlstone Medical Ltd, QIAGEN, Thermo Fisher Scientific, and Veracyte, Inc.

The answers to the following key questions can be derived from this report:

Key Topics Covered

Executive Summary

1 Product Definition1.1 Inclusions and Exclusions

2 Research Scope2.1 Scope of Work2.2 Key Questions Answered in the Report

3 Research Methodology3.1 Global Minimally Invasive Biopsy Technologies Market: Research Methodology3.1.1 Primary Data Sources3.1.2 Secondary Data Sources3.1.3 Selection Criteria for Company Profiles

4 Industry Analysis4.1 Industry Ecosystem4.2 Regulatory Framework and Government Initiatives4.2.1 Liquid Biopsy: Regulatory Framework4.2.1.1 Liquid Biopsy: Regulations in the U.S.4.2.1.2 Liquid Biopsy: Regulations in Other Countries4.2.2 Optical Biopsy and Other Technologies: Regulatory Framework4.2.2.1 Optical Biopsy and Other Technologies: Regulations in the U.S.4.2.2.2 Optical Biopsy and Other Technologies: Regulations in Europe4.2.2.3 Optical Biopsy and Other Technologies: Regulations in Other Countries4.3 Patent Analysis4.3.1 Liquid Biopsy: Patent Analysis4.3.2 Optical Biopsy: Patent Analysis4.4 Physician's Perception

5 Competitive Landscape5.1 Key strategies and Developments5.1.1 Partnerships, Alliances, and Business Expansions5.1.2 New Offerings5.1.3 Funding Activities5.1.4 Procurement and Sales Agreements5.1.5 Regulatory and Legal Developments5.1.6 Mergers and Acquisitions5.2 Market Share Analysis5.2.1 Market Share Analysis: Global Liquid Biopsy Market5.2.2 Market Share Analysis: Global Optical Biopsy Market5.2.3 Market Share Analysis: Global Other Technologies Market5.3 Growth Share Analysis5.3.1 Growth Share Matrix (by Technology)5.3.2 Growth Share Matrix (by Therapeutic Application)5.3.3 Growth Share Matrix (by Region)

6 Global Minimally Invasive Biopsy Technologies Market, 2018-20306.1 Assumptions and Limitations6.2 Key Findings and Opportunity Assessment6.3 Global Minimally Invasive Biopsy Technologies, Market Scenario6.3.1 Global Minimally Invasive Biopsy Technologies Market Size and Forecast (2018-2030)6.3.2 Market Dynamics6.3.2.1 Overview6.3.2.2 Impact Analysis6.3.2.3 Market Drivers6.3.2.3.1 Rising Global Burden of Cancer6.3.2.3.2 Increasing Number of Cross-Industry Collaborations6.3.2.3.3 Growing Prominence of Precision Medicine6.3.2.4 Market Restraints6.3.2.4.1 Uncertain Regulatory Requirements6.3.2.4.2 Lack of Favorable Reimbursement Policies6.3.2.4.3 Technical Challenges Associated with the Analysis of Circulating Biomarkers6.3.2.5 Market Opportunities6.3.2.5.1 Business Expansion in Emerging Economies6.3.2.5.2 Integration of Artificial Intelligence (AI)6.3.2.5.3 Rising Number of Initiatives by the Government6.4 Market Estimation Method

7 Global Minimally Invasive Biopsy Technologies Market, by Technology, 2018-20307.1 Overview7.2 Global Liquid Biopsy Market Scenario, 2018-20307.2.1 Principle and Advantages of Liquid Biopsy7.2.2 Key Findings and Opportunity Assessment7.2.3 Global Liquid Biopsy Market, Market Size and Forecast (2018-2030)7.2.3.1 Market Dynamics7.2.3.1.1 Impact Analysis7.2.3.1.2 Market Drivers7.2.3.1.2.1 Increasing Demand for Liquid Biopsy Tests7.2.3.1.2.2 Recent Product Launches and Approvals7.2.3.1.2.3 Strong Pipeline7.2.3.1.3 Market Restraints7.2.3.1.3.1 Uncertain Regulatory Requirements7.2.3.1.3.2 Lack of Adequate Reimbursement7.2.4 Global Liquid Biopsy Market Segmentation7.2.4.1 Global Liquid Biopsy Market (by Product), 2018-20307.2.4.1.1 Overview7.2.4.1.2 Tests7.2.4.1.3 Kits and Consumables7.2.4.1.4 Instruments7.2.4.2 Global Liquid Biopsy Market, by Circulating Biomarker, Market Size and Forecast (2018-2030)7.2.4.2.1 Overview7.2.4.2.2 Circulating Tumor DNA (ctDNA)7.2.4.2.3 Circulating Tumor Cells (CTCs)7.2.4.2.4 Cell-Free DNA (cfDNA)7.2.4.2.5 Extracellular Vesicles and Others7.2.4.3 Global Liquid Biopsy Market, by Clinical Application, Market Size and Forecast (2018-2030)7.2.4.3.1 Overview7.2.4.3.2 Treatment Monitoring7.2.4.3.3 Prognosis and Recurrence Monitoring7.2.4.3.4 Treatment Selection7.2.4.3.5 Diagnosis and Screening7.2.4.4 Global Liquid Biopsy Market, by Therapeutic Application, Market Size and Forecast (2018-2030)7.2.4.4.1 Overview7.2.4.4.2 Lung Cancer7.2.4.4.3 Breast Cancer7.2.4.4.4 Prostate Cancer7.2.4.4.5 Colorectal Cancer7.2.4.4.6 Blood Cancer7.2.4.4.7 Other Types of Cancer7.2.4.4.8 Non-Oncology Applications7.3 Global Optical Biopsy Market Scenario, 2018-20307.3.1 Principle and Advantages of Optical Biopsy7.3.2 Key Findings and Opportunity Assessment7.3.3 Global Optical Biopsy Market, Market Size and Forecast (2018-2030)7.3.3.1 Market Dynamics7.3.3.1.1 Impact Analysis7.3.3.1.2 Market Drivers7.3.3.1.2.1 Recent Product Launches and Approvals7.3.3.1.2.2 Significant Number of Funding and Investments7.3.3.1.2.3 Anticipated Product Launches7.3.3.1.3 Market Restraints7.3.3.1.3.1 Lack of Favorable Reimbursement7.3.3.1.3.2 Stringent Regulatory Guidelines7.3.4 Global Optical Biopsy Market (by Therapeutic Application), 2018-20307.3.4.1 Overview7.3.4.2 Oncology7.3.4.3 Non-Oncology Applications7.4 Global Other Technologies Market Scenario, 2018-20307.4.1 Overview7.4.2 Key Findings and Opportunity Assessment7.4.3 Global Other Technologies Market, Market Size and Forecast (2018-2030)7.4.3.1 Market Dynamics7.4.3.1.1 Impact Analysis7.4.3.1.2 Market Drivers7.4.3.1.2.1 Ongoing Strategic Collaborations and M&A Activities7.4.3.1.2.2 Strong Product Pipeline7.4.3.1.3 Market Restraints7.4.3.1.3.1 Poor Reimbursement Scenario7.4.3.1.3.2 Limited Scope of Expansion in Emerging Economies7.4.4 Global Other Technologies Market, (by Therapeutic Application)7.4.4.1 Overview7.4.4.2 Lung Cancer7.4.4.3 Melanoma7.4.4.4 Thyroid Cancer7.4.4.5 Non-Oncology Applications

8 Global Minimally Invasive Biopsy Technologies Market, (by Region), 2018-20308.1 Overview and Key Findings8.2 North America8.3 Europe8.4 Asia-Pacific8.5 Latin America and the Middle East8.6 Rest-of-the-World

9 Company Profiles9.1 Abcodia Ltd.9.2 Adaptive Biotechnologies9.3 Biocept, Inc.9.4 Caliber Imaging & Diagnostics9.5 Chronix Biomedical9.6 DermTech9.7 F. Hoffmann-La Roche Ltd.9.8 Guardant Health, Inc.9.9 Mauna Kea Technologies9.10 Myriad Genetics9.11 NeoGenomics Laboratories, Inc.9.12 Owlstone Medical Ltd.9.13 QIAGEN9.14 Thermo Fisher Scientific9.15 Veracyte, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/3128v2

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-minimally-invasive-biopsy-technologies-markets-2019-2030---a-4-billion-opportunity-with-focus-on-liquid-biopsy-optical-biopsy-and-brush-biopsy-pigmented-lesion-assays-and-breath-biopsy-301035982.html

SOURCE Research and Markets

Read more:
Global Minimally Invasive Biopsy Technologies Markets, 2019-2030 - A $4+ Billion Opportunity with Focus on Liquid Biopsy, Optical Biopsy, and Brush...

Heading into this year, I was passionate about getting a very important message in front of investors.

Source: Shutterstock

It was my thesis that the next decade would not only be the most innovative in history, but that the stock market would experience its largest gains ever.

The start of 2020 as brutal as it has been reminds me of 1990. Stocks had already been in a bull market for eight years when the ball dropped on 1989 and ushered in the new decade. Most experts believed the bull market was over and that the 1990s would be a lost decade.

Boy, were they wrong.

The 1990s went on to become one of the greatest decades for stocks. Little technology companies youd never heard of became household names. Dell Computer now Dell Technologies (NYSE:DELL) gained over 91,000% during the 1990s. The biggest gains of the decade were driven by a plethora of new technologies centered around the internet and personal computing.

Today, we are now three months into the 2020s and stocks are in a similar situation. We entered the decade on the back of a 10-year bull market, only to slide quickly into a bear market.

Most people dont realize this, but the Dow did something similar in 1990. It fell by 19.5% essentially a bear market to start the decade before powering higher. I believe we will look back at the current sell-off and see it as the last great buying opportunity before a booming decade.

The selling is creating buying opportunities in investment trends that wont slow due to the pandemic. In fact, they could even accelerate due to the changing global landscape. Lets take a look at a few

Robotics:According to the editorial board atScience Robotics, robots could be an alternative to humans when it comes to certain healthcare tasks. Especially during a pandemic. Robots could collect lab results, automate lab tests, and help disinfect the patient rooms. In China, it was deemed too dangerous for humans to make critical deliveries of medicine and food into infected areas, so the country turned to robots.

Genomics:The future of healthcare will be based on advances in both technology and medicine. The latter will rely on the field of genomics. In the coming decade, it will be the norm to have your genome sequenced. This information will help create personalized medicine for each patient, as well as help speed up the creation of new drugs.

The response to the coronavirus is a great example of how medicine is evolving. In 10 years, this type of pandemic would not be an issue. The combination of artificial intelligence (AI), quantum computing, and genomics would create a vaccine within days.

Tele-everything:The biggest change to our lives throughout this ordeal has been the self-isolation. Either through a government mandate or by choice, most people around the globe are staying inside and not going about their normal activities. This has led to a work-from-home, school-from-home, and even workout-from-home situation.

The companies behind this trend are here to stay. When the pandemic is over, people will go back to work, school, and their local fitness facilities. But the tele-everything trend is not going away. In some circumstances, it is more convenient than what we were accustomed to. Everything from software companies to one of my favorite stocks,Teladoc (NYSE:TDOC), to online education will be pushed to grow faster and quicker after the pandemic.

Even though a lot of the stocks in these trends have been beaten down in the last month, the trends themselves are not dead. Nothing I mean nothing in life goes straight up. When it comes to the stock market, the strongest trends will hit speed bumps but those bumps offer investors opportunities.

Let me be straight with you. If you want to be wealthy, you must buy into high-growth, long-term trends. And to make the BIG money you need to buy when everyone else is selling.

That day is today.

Matthew McCall left Wall Street to actually help investors by getting them into the worlds biggest, most revolutionary trends BEFORE anyone else. The power of being first gave Matts readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA) and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now. Matt does not directly own the aforementioned securities.

More:
3 High-Growth Trends to Invest In Now - Investorplace.com

The current pandemic situation that the world is suffering due to the SARS-CoV-2 coronavirus is hopelessly transforming any forecast that would have been set for 2020 in most environments. Even more in the field of health, where efforts are being made to end this situation.

In the case of personalized medicine in Spain, this year they expected to solve technological, social, legal, ethical and healthcare challenges with the possible approval of a strategic plan by the Government, which has been analyzed by the Senate for more than two years with the collaboration of experts in the field. A long-awaited regulation that it is more than likely to delay again.

From the point of view of the investigation, advances were outlined in CRISPR / Cas9, a molecular tool to edit or correct the genome of a cell. Also in a more efficient and combined use of the so-called micas omics sciences: genomics, metabolomics, epigenomics, etc., which, even though they have been going for several years, are still at the dawn of their journey.

Companies like OncoDNA, a company specialized in precision medicine for the treatment and diagnosis of cancer, continue working to promote new advances in this last section. She has spent several years dedicated to carrying out genomic analysis of samples from cancer patients, tissue and blood (liquid biopsy), to offer more information on the genetic profile of each tumor to specialists and thus be able to determine the most appropriate therapy for the patient.

Over the past 12 months the number of genes analyzed has been expanded in their tests, arriving their OncoDEEP and OncoSTRAT & GO solid biopsy panels until 313 and even, combining tissue analysis with liquid biopsy in stage IV solid tumors. Incorporating new essential biomarkers to know the peculiarities that can occur in each patient.

Pending all the news

In the same way, researchers continue to be very aware of the different publications that are appearing in the most prestigious media in the world in the field of oncology to improve their services. An example of this were the changes adopted a few months ago in your OncoSTRAT & GO test.

This new version includes the study of germline mutations in the ATM, BRCA1 and BRCA2 genes, as well as other pathway genes involved in homologous recombination, which can also be treated with PARP inhibitors. A solution that is already available and that is especially useful in patients with ovarian, prostate, pancreas and triple negative breast cancer.

In laboratories, and with the collaboration of different hospitals and specialized cancer centers around the world, work is also being done on this combination of omics sciences, which could offer a much more individualized view of the molecular profile of each patient, thus improving their prospects of success against cancer. Even to turn them into an effective tool to predict and assume preventive intervention strategies.

More advances in big data

Processing large amounts of data it will also continue to be key in the field of personalized medicine. Increasingly, taking into account that the progressive evolution of the micas omics will require technologies that translate their results into a language understandable to healthcare professionals.

In the oncological case they begin to emerge computer applications capable of processing and translating in a very short time the large amount of genetic information that each genomic analysis offers us. As with OncoKDM, an intelligent online genomic interpretation platform that responds to the most immediate needs of oncologists, pathologists, and other specialists in molecular biology.

It is capable of bringing together all the information that has been collected about a patient, such as the results of any genomic technology, molecular pathology data or clinical information, analyzing and interpreting it effectively at a clinical and biological level in a few minutes. In this way, it facilitates the oncologists decision making when choosing the ideal therapy for the patient or searching for clinical trials available in their country of origin , explains Adriana Terrdez, director of OncoDNA in Spain and Portugal.

It is to be expected that solutions such as those of genomic tests or software and platforms for the processing and interpretation of genomic data continue to evolve in the future in order to improve cancer patient care and make the best decisions in each case. It is working day by day in order that the news arrive as soon as possible. Even in these uncertain times.

//

Visit link:
COVID-19 transforms the challenges of Personalized Medicine for 2020 - Explica

According to a new report published by Proficient Market, titled, Global Biochip Market by Product Type (DNA Chips Market, Lab-On-A-Chip Market, Protein Chips Market & other) and by End-Users/Application (Biotechnology and Pharmaceutical Companies, Hospitals and Diagnostics Centers, Academic & Research Institutes & Other) Global Market Share, Forecast Data, In-Depth Analysis, and Detailed Overview, and Forecast, 2015 2027 The report has offered an all-inclusive analysis of the global biochip market taking into consideration all the crucial aspects like growth factors, constraints, market developments, top investment pockets, future prospects, and trends. At the start, the report lays emphasis on the key trends and opportunities that may emerge in the near future and positively impact the overall industry growth.

According to the report, Global Biochip Market in 2019 stood at USD 14 billion and is expected to reach USD 62.82 billion by 2027 growing at a CAGR of 20.63% from 2020 to 2027.

Get Free Sample PDF (including full TOC, Tables and Figures) of Biochip Market @ https://proficientmarket.com/sample/1183

A biochip is a collection of microarrays organized on a solid substrate, allowing thousands of complex biochemical reactions, to determine various biological data, for instance, decoding the genes in less time. The biochip-based analysis is primarily used for on-site diagnosis. Biochips also undergo other diagnostic applications such as microarray technique, microfluidic technologies, & biosensors. A biochip can also provide analytical data regarding organic molecules associated with the living organisms. It helps in identifying airborne toxins, environmental pollutants, gene sequences, & other biochemical constituents.

Biochip Market Key Players: The research study includes profiles of leading companies operating in the global biochip market. Key players profiled in the report include:

Abbott Laboratories Agilent Technologies PerkinElmer Inc. Fluidigm Corporation Illumina GE Healthcare Bio-Rad Laboratories Inc. Cepheid Inc. Thermo Fisher Scientific F. Hoffmann-La Roche AG.

Do enquire to get a strategic overview of the market, Access Research Methodology Prepared By Experts at: https://proficientmarket.com/buying-request/1183

Thermo Fisher Scientific Inc. completed the acquisition of Affymetrix Inc., a leading provider of cellular and genetic analysis products. This acquisition helped Thermo Fisher to strengthen its leadership in biosciences, as well as acquire new genetic analysis capabilities to better serve clinical and applied markets.

Drivers for the Global Biochip Market: The increased use of biochips due to increasing cancer treatment and diagnostics. Rise in personalized medicine, drug discovery and life science research, need for high speed diagnostics and increased government funding are some of the key factors driving the growth for global biochips market. In addition, increasing healthcare awareness is also fueling the growth of global biochips market. Thus all these factors led to boosting the growth of the biochips market.

Opportunities for the Global Biochip Market: Rapid growing application of biochips will drive the market growth during forecasted period. While the Technological advancements and new product launches in the market are witnessed to augment the growth of the biochips market in forthcoming years. However, Rising demand of biochips in developing countries is witnessed to increase the market share of biochips. Moreover the Increasing adoption of personalized medicines by households will also propel the growth of the biochips market. Thus, all these factors will provide lucrative opportunities for the growth of the biochips market.

Restrains for the Global Biochip Market: The Strict government regulatory guidelines related to biochips are hampering the growth of the market. While the High instrument costs will also restrain the growth of this market. Lack of proper knowledge about biochip technology is a prominent restraint lowering the demand for biochip products. The irregularities arriving in healthcare coverage around the world are also more likely to challenge the growth of biochips market. Variable cost and adoption of biochip technologies is likely to affect the personalisation of medicine, eventually lowering the revenues of the global biochips market. Thus all these factors are creating a negative impact at the growth of the biochip market.

Region Wise, Global Biochip Market Analysis: Report covers the region wise analysis, global Biochip market can be segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Among all, North America leads the global Biochip market share followed by Europe and Asia Pacific. While the North America leads the global Biochip market due to the factors such as presence of well-established players, advanced informatics infrastructure, presence of experts and skilled workforce, and ongoing genomic R & D practices on a large scale in the region. While the rising R & D investments in genomic research is driving the growth of the market. Moreover, growing awareness regarding genetic tests for disease risk assessment and prevention is anticipated to have a positive impact on the growth of the regional market..

Access Full Report, here: https://proficientmarket.com/report/1183/global-biochip-market

Global Biochip Market: Product analysisDNA Chips MarketGene ExpressionSNP GenotypingCancer Diagnosis & TreatmentGenomicsDrug DiscoveryAgricultural BiotechnologyLab-On-A-Chip MarketClinical DiagnosticsGenomicsIVD & POCProteomicsDrug DiscoveryProtein Chips MarketProteomicsExpression ProfilingDiagnosticsHigh-Throughput ScreeningDrug DiscoveryOther Cell ArraysTissue Arrays

On the basis of type DNA Chips Market, accounted for largest share of total revenue generated due to the increasing use of DNA chip products. The use of DNA chip has empowered the scientific community by enabling measurement of the expression levels of large numbers of genes simultaneously. A DNA chip involves an array of microscopic spots each carrying numerous single-stranded oligonucleotides and are widely being used in biomedical research activities. Thus due to its huge utilization led to the growth of this segment which is fueling the biochip market.

Global Biochip Market: Application analysisBiotechnology and Pharmaceutical CompaniesHospitals and Diagnostics CentersAcademic & Research InstitutesOther

The demand of Global Biochip Market is highest from Biotechnology and Pharmaceutical Companies due to the numerous features offered by it. The utilization rate of biochips in biotechnology and pharmaceutical companies was high. The hospitals & diagnostics is the second fastest growing segment due to the adoption of biochip in new drug discovery as well as in point-of-care diagnostics has increased the consumption of these biochips in hospitals & diagnostics centers. Thus all these factors led to increase usage of biochips in this sectors which is propelling the growth of the biochip market.

Global Biochip Market: Region analysisNorth America: U.S., Canada, MexicoEurope: U.K., France, Germany, Spain, Italy, Rest of EuropeAsia Pacific: China, Japan, South Korea, ASEAN, IndiaRest of Asia Pacific: Latin America, Brazil, Argentina, Colombia, Rest of L.A.Middle East and Africa: Turkey, GCC, UAE, South Africa, Rest of Middle East

The report can be customized as per client requirements. For further queries, you can contact us on [emailprotected] or +1-773-800-2974. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Read the full press release and latest news of this report, here: https://proficientmarket.com/press-release/1188/global-biochip-market

About Us:Proficient Market is the leading research company offering both tactical and strategic support to all our customers. Customer satisfaction is our goal and that is why, we have a team of skilled and experienced specialists with the ability to do data mining, information management, and revenue enhancement solutions to ensure that our clients make informed decisions when coming to investing in the market. Our happiness is when we help our clients grow their business, strengthen the brands and educate their members or consumers through the ever-new fun research methods developed by our team.

Contact Us:Proficient Market1st Floor, Harikrishna Building,Samarth Nagar, New Sanghvi,Pune- 411027 IndiaTel: +91-8149441100 (GMT Office Hours)USA: +17738002974Email: [emailprotected]Web: proficientmarket.com

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at [emailprotected].

WiredRelease

Visit WiredRelease's Website

Here is the original post:
Insights On The Global Biochip Market To 2027 Featuring Abbott Laboratories, Agilent Technologies, PerkinElmer Inc., Fluidigm Corporation, Illumina,...

Technological advancements and scientific breakthroughs have propelled the assessment of pathogenesis and fostered precision medicine industry. Precision medicine has become instrumental in alleviating suffering pertaining to medical care, owing to unintended side effects resulting from one-size-fits-all approach.

Rapid transformation towards precision medicine is also believed to reduce the cost of treatment by doing away with inapt treatment plans. Precision medicine has become pivotal in leveraging doctors to select treatments based on a genetic understanding of the patient's disease and creating a personalized treatment plan.

Genetic laboratory industry is believed to be using processing power, data, science and operators to enhance the results for costly and debilitating diseases. In terms of technology, big data is touted to set the trend in precision medicine market as the technology enables more precision and tailoring compared to linking diverse data sets to showcase casual pathways. Dependence of precision medicine on big data has propelled the biomedical research.

Request sample copy of this report @ https://www.decresearch.com/request-sample/detail/671

Stakeholders have shown increased traction towards big data analytics for it complements clinical care and streamlines public health surveillance. Notably, big data has the ability to track and predict major outbreaks to boost public healthcare resources and disseminate healthcare message to patients using social media.

Profound deployment of sensing technologies has fared well for big data analytics. With soaring trend for implantable and wearing sensing has been in line with the increased bandwidth and improved microelectronics.

With the wealth of information to different disease, big data revolution has offered an opportunity to embrace AI and machine learning algorithms in the massive data set. Global Market Insights, Inc., predicts big data analytics market share to have been registered at 12% in 2019, citing influx of complex of data generating in healthcare sector.

Make Inquiry about this report @ https://www.decresearch.com/inquiry-before-buying/671

Recent advancements in technology indicate that stakeholders are increasingly using precision medicine in oncology. With neurological disorders being one of the leading causes of morbidity and disability globally, precision medicine has grown in significance. The disorder is expected to grow on the heels of increased life expectancy and population growth leading to economic burden and health issues.

Oncology has opened avenues for precision medicines as central nervous system (CNS) market share in 2019 was pegged at over 24%, mainly attributed to soaring prevalence of CNS disorders globally.

Use of precision medicine in healthcare IT companies will become more noticeable in the next five years owing to soaring demand for technologically advanced equipment for analysis, rapid integration and storage of patient data. In bid to push to the capabilities in data analysis, data acquisition, and analytics-based decision making, established technology players and startups are adopting precision medicine.

Several healthcare IT companies are offering operation and software tools for healthcare systems to adopt personalized medicine. Healthcare IT companies segment was pegged at around US$ 16 bn in 2019.

With the time ideal for disruption through strategic business model owing to changing healthcare dynamics, stakeholders are increasingly inclined towards infusing investment in MEA. Leading companies believe MEA to emerge as a prominent growth ground for the industry.

While massive data has been captured for advanced economies, dearth of data in African countries and most of the Gulf countries has signified the importance of precision medicine. Further, burgeoning population has also been one of the factors fueling growth in the region. MEA market was pegged at over USD 3.0 billion in 2019 and is estimated to expand at a CAGR of more than 10.0% during the forecast period.

View original post here:
Precision Medicine Market growth outlook with industry review and forecasts - GroundAlerts.com

object(stdClass)#31465 (59) { ["id"]=> string(4) "5792" ["title"]=> string(69) "How Blockchain Improves Logistics: Benefits, Drawbacks, and Use Cases" ["alias"]=> string(66) "how-blockchain-improves-logistics-benefits-drawbacks-and-use-cases" ["introtext"]=> string(177) "

The blockchain technology and logistics industry tend to be quite profitable for each other. Additionally, this collaboration brings benefits to carriers and customers.

In this article, well discuss all you need to know about blockchain in the logistics sector.

Blockchain allows optimizing logistic processes in the real-time mode. This technology tends to improve the relationship between shippers and carriers.

We've singled out six main advantages of using blockchain in the logistics sector. Lets discuss them more precisely.

There are a lot of documents required for the transportation process. For example, a bill of lading or B/L. It stands for an agreement that consists of transportation terms, conditions, and other issues.

Blockchain allows recording all the steps. As a result, any participant can look through the delivery chain. If something happens, recorded information will report a problem.

Blockchain allows optimizing routes and delivering faster. In this case, smaller companies can compete with bigger ones, offering faster routes.

As a result, its possible to reduce expenses on the shipping process.

Blockchain simplified the process of goods certification. The combination of IoT and blockchain allows creating smart contracts.

Transactions made on blockchain are secure. Its impossible to change something in the transaction. It leads to decreasing fraudulent operations.

Intermediaries stand for agents that take part in the transportation chain. However, withlogistics software development, the industry doesnt need such specialists.

Weve already mentioned smart contracts. They tend to reduce time and expenses. Also, both parties have an opportunity to automate the validation process, manage obligations, and so on.

There were main blockchain advantages. As you can see, this technology can be quite profitable for the logistics industry.

Of course, there are some disadvantages of using blockchain technology. Lets discuss them more precisely.

Blockchain allows automating supply processes. As a result, there is no need for various specialists. The number of unemployed workers will rise.

Businesses that use blockchain technology should have a standard process. Unfortunately, these days, businesses dont have one.

Its required to create a standard process on the government level. So, businesses can follow it to avoid some common problems.

Its evident that blockchain development is expensive and time-consuming. Additionally, its required to have powerful hardware.

Also, there are expenses on specialists that are experienced in blockchain integration.

So, blockchain is a quite expensive technology that requires additional preparation before using it. However, some companies have already integrated blockchain and got some profit.

Blockchain makes it easy to track goods during shipment. Additionally, the companies have an opportunity to monitor the conditions of the packages.

As a result, its possible to detect broken goods, spoilt products, and so on.

Of course, such opportunities lead to decreasing unnecessary expenditures.

Successful story. Walmart cooperates with IBM to use the blockchain technology in the logistics. The system allows seeing what products are sold. Also, its possible to know the location of the product (the particular warehouse). The company claims that the supply process becomes more transparent.

Blockchain allows reducing the number of documents required for transportation. Additionally, the number of mistakes will also decrease due to automatization. The shipping terms fulfill more precisely.

Let's face it payments are important for any business. Blockchain makes this process secure. For example, its possible to make transactions with such cryptocurrencies as Bitcoin. As a result, the payment process is secure and transparent. Also, such solutions improve international processes.

Successful story. Tallysticks has made a platform that simplified payment processes using blockchain. The solution offers smart contracts that can be customized depending on the business needs and requirements.

Blockchain gives end consumers an opportunity to simplify the authenticity of the goods. There are platforms with data about product origin, quality, fineness, and others.

This technology gives clients transparency. As a result, people trust companies more.

Blockchain makes cooperation easier. For example, enterprises can cooperate with small companies to deliver goods faster. Such a solution is profitable for both parties.

These days, companies can cooperate with each other without intermediaries. It leads to cost reduction and improved delivery processes.

Successful story. ShipChain platform uses blockchain to improve cooperation. For instance, the service allows tracking the delivery from the warehouse to the buyer's door. It leads to better customer experience and satisfaction.

The delivery process is long and expensive. Also, there can occur various delays due to weather conditions and other issues.

Usually, to manage such issues, companies hire lawyers. However, blockchain changes the situation. The transportation process is tracked from the beginning to the end. So, both parties can see any changes in the route.

Also, the parties can monitor any issues connected to the delivery and decide whose fault they were.

Blockchain technology innovates the logistics sector. The companies can simplify the delivery process, making routes shorter.

All these solutions lead to customer satisfaction. As a result, the clients trust companies and order goods or services more often.

The main advantage of blockchain is transparency. Business owners, as well as end consumers, have an opportunity to track the delivery process. Also, customers can ensure that during the delivery the storing conditions were followed.

However, developing blockchain-based solutions is an expensive and time-consuming process. Companies have to prepare beforehand and single out the requirements of the final product.

Link:
The Growing Role of Artificial Intelligence in the Pharmaceutical Industry - BBN Times

According to the latest study conducted by Trends Market Research (TMR) the global market for precision medicine is anticipate grow manifold, reflecting a robust CAGR of over XX% during 2018 to 2025.

Rapid augmentation of the medicine industry across the globe will certainly benefit the global market forprecision medicine. In addition, factors such as growing infrastructural development, higher investments, streamlined drug approval systems along with companion diagnostics are expected to favor the overall market growth during the assessment period. Cost-effective DNA profiling and increasing prevalence of carcinogenic diseases worldwide are additional factors that are projected to propel the market growth. Moreover, apt storage of genome data is of great significance to the global market for precision medicine as demand for data medicare is on the rise. However, acute data storage capacity, data privacy breach and discrepancies in funding systems and hefty price tag of personalized drugs may deter the market growth in the near future.

Enquiry More About This Report:https://www.trendsmarketresearch.com/report/sample/3437

The global market for precision medicine has been categorized into various parent segments that are further segmented into smaller sub-divisions.

On the basis of technology, next-gen sequencing, bioinformatics and drug discovery technology are expected to be the technologies highlighting the expanding the market width in forthcoming years. Based on applications, the oncology segment is expected to witness an overwhelming growth and is estimated to reach US$ XX Billion over 2025, reflecting a staggering XX% CAGR. This is primarily owing to increasing prevalence of tumor-related disease amongst the global geriatric population. On the other hand, increasing cases of arthritis will favor the growth of immunology segment, which is expected to surpass US$ XX Million in revenues by 2025 end.

Vendor News

Key players operating in the global market for precision medicine include Eli Lilly And Company, Novartis AG, AstraZeneca and Laboratory Corporation of America Holdings. Most of the companies are implementing market strategies involving mergers, tie-ups and acquisitions. Increasing collaboration between healthcare and IT is expected to deliver fruitful gains to the market, expanding the overall business canvas for the stakeholders in the upcoming years.

Request For Report Discounts @ https://www.trendsmarketresearch.com/report/discount/3437

The popularity of precision medicine has grown significantly across various parts of the world, hence on the basis of region, the markets for precision medicine in Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa (MEA) is set to achieve new figures of growth over the next eight years. Precisely, the market in North America is expected to present new lucrative opportunities, occupying over XX% share of the market during the forecast period. In addition, the region is estimated to surpass a market valuation of over US$ XX Million by the end of 2025.

The US and Canada will be the heavyweights of the global market owing to the existence of well-established medical industries in both the countries. In Europe, the market is expected to witness a steady growth and will increase its revenues charts close to US$ XX Million, riding on a healthy CAGR of over XX% during the assessment period. This is largely due to the increasing demand for precision medicines in countries such as France, UK, Italy and Germany. The Asia Pacific region is another region which is considered to be full of business potentials. The region is projected to increase at over XX% CAGR to reach approximately US$ XX Million by 2025 end. The market in APAC will be heavily dominated by Japan, while, India and China will compete for the second spot. Likewise, the in Latin America the market is expected to surge at a pace in terms of revenue over 2025. However, MEA will witness a sluggish growth of the market which is attributed to the lack of initiatives for conductive extensive research and development activities.

Make an Inquiry before [emailprotected] https://www.trendsmarketresearch.com/checkout/3437/Single

Visit link:
Precision Medicine Market to Witness a Healthy Growth during 2018-2025 - Curious Desk

Florida sees increased coronavirus tests and a surge in cases

The latest numbers show the state has tested about nine times more people for coronavirus than it did just a week ago. At the same time, the number of positive cases has surged. It makes sense that if you test more, youll find more coronavirus. But thats only a partial explanation for the swift rise in Covid-19 cases. USF Public Health Professor Jay Wolfson says the lack of testing up until now means that people who didnt know they were infected could have given the virus in a worst case -- to a thousand people in a week. [Source: Health News Florida]

Florida to allow recently retired health care workers to return to work

Gov. Ron DeSantis said Monday that he plans to sign an executive order allowing recently retired law enforcement and health care professionals to return to the workforce to help fight coronavirus. We need to have folks that are willing to return to service, DeSantis said. DeSantis said his order will allow recently retired law enforcement and health care personnel to return to work immediately. [Source: WESH]

Hotels could be used for medical surge

Health care facilities are preparing for the worst-case scenario: a medical surge that could overwhelm bed space inside hospitals. Some facilities are looking into other buildings and spaces that could be used to care for a large wave of COVID-19 patients. Dr. Stanley Marks, chief medical officer at Memorial Healthcare System in Broward County, talks about COVID-19 preparation efforts. [Source: WLRN]

Southwest Florida medical practice digests large growth plans

Lakewood Ranch physician Dr. Arun Khazanchi takes the future of the medical practice he leads, Florida Digestive Health Specialists, personally. As in personalized medicine. Like many physicians and health care providers, Khazanchi can see medicine is moving fast toward a world where biomarkers, genetic research and tailored treatments dominate health care no matter the payment system. [Source: Business Observer]

DeSantis orders Attorney General to investigate South Florida hospital

Florida Gov. Ron DeSantis called on the state attorney general Friday to investigate a South Florida hospital charging $150 per test for COVID-19, the disease caused by the novel coronavirus spreading rapidly across the state. While DeSantis did not name the hospital, Larkin Community Hospital operates a drive-thru testing site in Hialeah and charges $150 per test. [Source: WUSF]

ALSO AROUND FLORIDA:

What is a child health advocate in Florida? [NBC-2]From Gun safety to ATV safety, even sleep safety, child advocates at Golisano Childrens Hospital of Southwest Florida are focused on keeping children out of the hospital. A child advocate is somebody thats passionate about keeping kids safe in the community, whether that means one-on-one with the family, or one-on-one with kids, grandparents, said Sally Kreuscher, child advocacy program coordinator with Golisano Childrens Hospital.

Medical cannabis access an essential service sort of [The Lakeland Ledger]With nearly 328,000 Floridians officially registered as medical marijuana patients, the coronavirus has forced the states hand into declaring cannabis an essential component of health care. Unless, of course, youre a new patient in need of a card. In that case, you may be out of luck, for at least through the middle of next month.

Sarasota quilters sew face masks for health care workers [Sarasota Herald-Tribune]As the coronavirus pandemic mounts in the U.S. each day, the nation is facing a shortage of face masks for health care workers. The South Sarasota Modern Quilt Guild, like other sewing groups across the country, tapped into their talent to work on a solution. The guilds members have been busy at work for the past week sewing cotton face masks for health care professionals to wear on top of their disposable N95 masks.

Hillsborough among areas receiving hydroxychloroquine [WUSF]Hillsborough County is among the areas in Florida being hardest hit with coronavirus that will receive a shipment of hydroxychloroquine, a drug that is being touted by some as a possible treatment for the symptoms of coronavirus. During a news conference on Saturday, Gov. Ron DeSantis said he worked with David Friedman, the U.S. ambassador to Israel who he said he considers a friend -- to arrange the shipment from Israeli company Teva Pharmaceuticals.

Tags:Health Care eNews

Previous Health Care Updates:

View post:
Florida sees increased coronavirus tests and a surge in cases - Florida Trend

WASHINGTON: Researchers have created artificial proteins that can control the activity of genes and other molecules in living cells in predetermined ways, an advance that can be used to program the behaviour of more complex chemical and biological systems.

In the study, published in the journal Science, the scientists showed that the designer proteins can regulate the activity of genes inside the human immune system's T-cells, adding that the development may improve the safety and durability of future cell-based therapies.

The researchers, including those from the University of Washington in the US, explained that the proteins, like their electronic counterparts, logic gates, implement a Boolean function, which is a logical operation performed on one or more binary inputs that produces a single binary output.

They explained that these logic gates sense and respond to signals in predetermined ways.

Citing an example, the scientists said, the 'AND' gate produces output only when one input AND another are present.

When typing on a keyboard, pressing the Shift key AND the A key produces an uppercase letter A, they explained.

The novel protein logic gates, made from biological parts, aim to bring this level of control into bioengineered systems, the researchers added.

"Bioengineers have made logic gates out of DNA, RNA and modified natural proteins before, but these are far from ideal. Our logic gates built from de novo designed proteins are more modular and versatile, and can be used in a wide range of biomedical applications" said study senior author David Baker from the University of Washington.

Using proteins like the one currently developed, the scientists said, inputs such as the presence of two different molecules in a living cell can cause it to produce a specific output, such as activating or suppressing a gene.

"The whole Apollo 11 Guidance Computer was built from electronic NOR gates," said lead author Zibo Chen, a recent UW graduate student.

"We succeeded in making protein-based NOR gates. They are not as complicated as NASA's guidance computers, but nevertheless are a key step toward programming complex biological circuits from scratch," Chen added.

While recruiting a patient's own immune cells in the fight against cancer has worked for certain forms of the disease, targeting solid tumours with genetically engineered T-cells has proven challenging.

Based on earlier studies, the researchers believe this could in-part be due to T cell exhaustion.

Genetically altered T cells can fight for only so long before they stop working, they explained.

But with protein logic gates that respond to exhaustion signals, the scientists hope to prolong the activity of genetically modified T cells.

"Longer-lived T cells that are better programmed for each patient would mean more effective personalized medicine," Chen said.

Read the original:
Researchers develop novel 'smart' proteins programmed to turn genes on and off - Economic Times

TOKYO--(BUSINESS WIRE)--CureApp, Inc. (Head Office, Chuo-ku, Tokyo; President and CEO, Kohta Satake, M.D.), developer of software as a medical device Digital Therapeutics mobile applications, has launched a Phase 3 multicenter, randomized comparative study (clinical trial) of "Digital Therapeutics for hypertension in Japan with various partners including Professor Kazuomi Kario, M.D., Ph.D., the Division of Cardiovascular Medicine, the Department of Medicine, and Jichi Medical University School of Medicine.

This study will evaluate the efficacy and safety of "Digital Therapeutics" in patients with essential hypertension who have not received an orally administered antihypertensive drug treatment. Patients will be divided into two groups; those using "Digital Therapeutics" in addition to lifestyle changes set according to the Guidelines for the Management of Hypertension 2019 (the "Guidelines) (*1), and those only adopting said lifestyle habit changes without using Digital Therapeutics. The primary criteria for evaluation is the change from the baseline in mean 24-hour systolic blood pressure*1 at 12 weeks after treatment begins, as measured by ambulatory blood pressure monitoring (ABPM)*2.

*1 Systolic blood pressure: Highest blood pressure in blood pressure measurement*2 Ambulatory blood pressure monitoring: Continuous measurement of blood pressure at certain intervals for 24 hours under normal lifestyle conditions. Blood pressure fluctuates due to various factors; this shows the daily variation in blood pressure (daily variation pattern).

Hypertension is the biggest risk factor for cerebrovascular and cardiovascular diseases (i.e. stroke, heart disease), and the annual death toll in Japan from these diseases attributed to hypertension is estimated to reach 100,000. The number of patients with hypertension in Japan is estimated approx. 43 million, and blood pressure is appropriately controlled in only 12 million of these patients (*1). The lifestyle improvements essential to hypertension treatment are difficult to sustain as they are largely dependent on a patients motivation or their workplace/home environment. At the same time, successful lifestyle intervention by medical institutions presents a challenge.

Under these circumstances, "Digital Therapeutics," a new treatment method utilizing mobile technology, aims to produce a strong therapeutic effect enabling patients to return to normal blood pressure and develop appropriate lifestyle habits by providing personalized, optimized treatment guidance to individual patients based on medical evidence and encouraging awareness/behavior changes. The hypertension treatment application used in this study will automatically analyze blood pressure and lifestyle characteristics of individuals from data that includes blood-pressure monitoring using a smart blood pressure monitor and lifestyle habit logs. This data will be used to provide optimal treatment guidance (advice on diet, exercise, sleep, etc., and information to encourage behavior improvements).

[Source](*1): The Guidelines for the Management of Hypertension 2019 [JSH2019], The Japanese Society of Hypertension (2019) https://www.jpnsh.jp/guideline.html

Professor Kazuomi Kario, M.D., Ph.D.Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine

Hypertension is the biggest risk factor for serious cardiovascular diseases such as stroke, myocardial infarction, and cardiac failure. Although thoroughgoing antihypertensive measures ensures to control these diseases, the control rate for hypertension in Japan is only about 30% at present. Reducing salt and alcohol intake, proper weight control, and exercise are very important in treating hypertension. However, these measures are difficult to maintain on a continual basis. Digital Therapeutics is the worlds first app to treat hypertension that provides full support for improving lifestyle habits directly lowering blood pressure by encouraging behavioral changes based on cognitive behavioral therapy. With its elaborate treatment program and the innovative application of new information technology, Digital Therapeutics assesses individual patients, and ensures an interactive information exchange between patients and physicians based on appropriate guidance with proven scientific evidence and patient behavior records. I hope to see this app serving as the first step toward realizing a self-cure of hypertension by closely monitoring the daily lives of individuals to help them improve their lifestyle habits.

Kohta Satake, M.D.President and CEO, CureApp, Inc.

The spread of Hypertension Digital Therapeutics as a treatment covered by health insurance will lead to preventing the progression of hypertension and inhibiting cardiovascular diseases. After this clinical trial, we aim to obtain regulatory approval and health insurance coverage. "Digital Therapeutics" can provide appropriate medical guidance to patients at home and outside the hospital, making it possible to provide high-quality personalized medical care to people of working age who find it difficult to make frequent visits to clinics, as well as people in remote areas. I feel certain that the increased use of "Digital Therapeutics," a new therapeutic approach using digital technology, will create new value in medical care for hypertension and contribute to reducing future medical costs.

About CureApp, Inc.

CureApp, Inc. is a MedTech start-up company that performs research and development and produces software as a medical device for disease treatments based on advanced software technology and medical evidence. CureApp pursues the research and development of "Digital Therapeutics, a disease treatment app, to establish a new form of medical service in Japan with a concept of an app that cures diseases.

"Digital Therapeutics" draws on a daily therapeutic process tailored to each patient to provide new therapeutic effects through analysis and guidance based on medical knowledge and evidence. Encouraging patients to improve their habits through raising their awareness and changing their behavior may also contribute to disease improvement. We clearly differentiate "Digital Therapeutics" app from the other unapproved healthcare applications as we aim to demonstrate the therapeutic effect of the "Digital Therapeutics" app in clinical studies, etc., obtain regulatory approval, and commercialize them as medical devices in the future. CureApp led the way in launching clinical studies of therapeutic application in Japan, and our first therapeutic application, Therapeutic Application for Nicotine Addiction," has completed clinical trials and is currently under application for regulatory approval. Development and clinical research on therapeutic applications for hypertension and NASH (non-alcoholic steatohepatitis) have also launched. We plan to leverage our U.S. subsidiary, which we founded last year, serve as a base of operations for broadly rolling out such "digital health solutions from Japan based on the model developed in Japan.

At present, the development status of "Digital Therapeutics" is as follows.

"Digital Therapeutics" is the registered trademark of CureApp, Inc.

General information of Jichi Medical UniversityName: Jichi Medical UniversityLocation: 3311-1 Yakushiji, Shimotsuke-shi, Tochigi-ken, JapanRepresentative: Toshio Oishi, Chairman of the BoardEstablished: February 1972URL: https://www.jichi.ac.jp/english/index.html

Corporate Profile of CureApp, Inc.Company Name: CureApp, Inc.President and CEO: Kohta Satake, M.D.Head Office Location: Kodenma-Cho YS Building 4th floor, 12-5, Nihonbashi Kodenma-Cho, Chuo-ku, Tokyo, JapanEstablished: July 31, 2014Business Description: Development of programmed medical devices, health-related mobile servicesURL: https://cureapp.co.jp/en/

See the original post:
Jichi Medical University and CureApp, Inc.: The First Phase 3 Clinical Trials of "Digital Therapeutics" for Hypertension Begin in Japan -...

DUBLIN, April 6, 2020 /PRNewswire/ -- The "Gut-on-a-Chip Market" report has been added to ResearchAndMarkets.com's offering.

The scope of this report is broad and covers various types of products available in the gut-on-a-chip market and the market's major geographical regions. Regions include North America, Europe, Asia-Pacific, and Rest of the World. The market size is estimated using data triangulation with both top-down and bottom-up approaches.

The market size was estimated by deriving the revenues of manufacturers. Revenue generated from the installation and maintenance of instruments has been excluded from this report.

This report explains the regional dynamics of the global market and regulatory scenario within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major players in the global gut-on-a-chip market.

The report includes:

Key Topics Covered

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Chapter 4 Market Analysis

Chapter 5 Market Breakdown by Application

Chapter 6 Market Breakdown by Region

Chapter 7 Regulatory Environment

Chapter 8 Competitive Landscape

Chapter 9 Company Profiles

Chapter 10 Recommendations and Conclusions

List of TablesSummary Table: Global Gut-on-a-Chip Market, by Region, 2018Table 1: Design Characteristics of Microfluidic Intestine ModelsTable 2: Global Gut-on-a-Chip Market, 2017 and 2018Table 3: Global Gut-on-a-Chip Market, by Application, 2018Table 4: Global Gut-on-a-Chip Market, by Region, 2018Table 5: Company Rankings in the Global Gut-on-a-Chip MarketTable 6: Beonchip: Product PortfolioTable 7: Beonchip: Recent Developments, 2018Table 8: Emulate Inc.: Product PortfolioTable 9: Emulate Inc.: Recent Developments, 2017-2019Table 10: Mimetas B.V.: Product PortfolioTable 11: Mimetas B.V.: Recent Developments, 2017-2019Table 12: TissUse GmbH: Product PortfolioTable 13: TissUse GmbH: Recent Developments, 2018 and 2019

List of FiguresSummary Figure: Global Gut-on-a-Chip Market Shares, by Region, 2018Figure 1: Global Organ-on-a-Chip Market Shares, 2018Figure 2: Global Gut-on-a-Chip Market Shares, by Application, 2018Figure 3: Global Gut-on-a-Chip Market Shares, by Region, 2018

For more information about this report visit https://www.researchandmarkets.com/r/ptwa46

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Visit link:
2020 Gut-on-a-Chip Industry Insights by Application & Region, Featuring Profiles of Beonchip, Emulate, Mimetas and Tissuse - PRNewswire

DUBLIN, March 20, 2020 /PRNewswire/ -- The "Population Health Management Market by Component (Software, Services), Mode of Delivery (On-premise Mode of Delivery, Cloud-based Mode of Delivery), End User (Healthcare Providers, Healthcare Payers, Government Bodies)] - Global Forecasts to 2025" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global population health management market is projected to reach USD 39.4 billion by 2025 from USD 22.9 billion in 2020, at a CAGR of 11.5% during the forecast period.

Government mandates and support for healthcare IT solutions, increasing use of big data analytics, and the need to curtail the escalating healthcare costs are the key factors driving the growth of the population health management market. In addition, emerging economies (such as Brazil, Russia, India, South Korea, and China), increasing focus on personalized medicine, and rising focus on value-based medicine are expected to offer lucrative growth opportunities for market players during the forecast period. However, data breaches, lack of skilled analysts, and interoperability issues are adversely impacting the growth of this market.

The software segment accounted for the larger share of the population health management market, by component, in 2019

On the basis of component, the population health management market is segmented into software and services. The software segment accounted for the largest share of the population health management market in 2019. Technological advancements in IT solutions and big data analytics, growth of cloud computing, and increasing penetration of the Internet across the globe are some of the key factors driving the demand for software-based HCIT solutions. Moreover, the adoption of population health management software to coordinate care processes is expected to increase in the coming years owing to its ability to reduce readmissions, increase cost-effectiveness, and enhance patient engagement.

By mode of delivery, the on-premise mode of delivery segment accounted for the largest market share in 2019

Population health management solutions are delivered to end users through the on-premise and cloud-based modes of delivery. The on-premise solutions segment accounted for the larger market share in 2019. The advantages offered by the on-premise mode of delivery, and the ability to reuse existing servers and storage hardware are supporting its increased adoption in the population health management market.

By end user, the healthcare providers segment accounted for the largest market share in 2019

On the basis of end user, the population health management market is segmented into healthcare providers, healthcare payers, and other end users. In 2019, the healthcare providers segment accounted for the largest share of the population health management market. The advantages offered by PHM solutions, growing pool of patients, increasing load on hospitals to integrate and manage patient data in a more efficient way, and the growing need to improve the affordability and accessibility of healthcare services are propelling the growth of the PHM solutions market for healthcare providers.

APAC is the fastest-growing market for population health management.

The population health management market in the APAC is expected to witness the highest CAGR during the forecast period. The growth of the Asia Pacific population health management market is driven by the rising medical tourism, the implementation of new ICT guidelines in Japan, investments and reforms to modernize China's healthcare infrastructure, the rapidly growing healthcare industry in India, and the implementation of IT programs in Australia and New Zealand. In addition, government initiatives for the adoption of HCIT, the growing geriatric population, rising prevalence of chronic diseases, increasing healthcare expenditure, and the rising purchasing power of consumers are also expected to support market growth in this region.

Story continues

Key Topics Covered

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights 4.1 Market Overview4.2 North America: Market, By Component & Country (2019)4.3 Population Health Management Market: Geographic Growth Opportunities

5 Market Overview 5.1 Introduction5.2 Market Dynamics5.2.1 Drivers5.2.1.1 Government Mandates & Support for Healthcare IT Solutions5.2.1.2 Increasing Use of Big Data Analytics5.2.1.3 Need to Curtail Escalating Healthcare Costs5.2.2 Restraints5.2.2.1 Huge Investments in Infrastructure to Set Up A Robust PHM Program5.2.3 Opportunities5.2.3.1 Emerging Markets5.2.3.2 Rising Focus on Personalized Medicine5.2.3.3 Increasing Focus on Value-Based Medicine5.2.4 Challenges5.2.4.1 Data Breaches5.2.4.2 Lack of Data Management Capabilities and Skilled Analysts5.2.4.3 Interoperability Issues

6 Population Health Management Market, By Component 6.1 Introduction6.2 Software6.2.1 Software is the Largest Component Segment of the Market6.3 Services6.3.1 Increasing Adoption of PHM Solutions & Indispensable & Recurring Nature of Services to Drive Market Growth

7 Population Health Management Market, By Mode of Delivery 7.1 Introduction7.2 On-Premise Mode of Delivery7.2.1 On-Premise Mode of Delivery Segment Accounted for the Largest Market Share in 20197.3 Cloud-Based Mode of Delivery7.3.1 Cloud-Based Mode of Delivery Segment to Register the Highest Growth in the PHM Market Between 2020 & 2025

8 Population Health Management Market, By End User 8.1 Introduction8.2 Healthcare Providers8.2.1 Growing Need to Improve the Profitability of Healthcare Operations is Driving the Use of PHM Solutions Among These End Users8.3 Healthcare Payers8.3.1 Increased Focus on Outcome-Based Payment Models has Driven the Demand for PHM Solutions Among Healthcare Payers8.4 Other End Users

9 Population Health Management Market, By Region 9.1 Introduction9.2 North America9.2.1 US9.2.1.1 The US is the Largest Market for Population Health Management Solutions9.2.2 Canada9.2.2.1 Deployment of Digital Health Initiatives is Boosting Market Growth in Canada9.3 Europe9.3.1 Germany9.3.1.1 Germany Dominates the European Population Health Management Market9.3.2 UK9.3.2.1 Increasing Public-Private Initiatives to Support the Adoption of PHM Solutions in the Country9.3.3 France9.3.3.1 Rising Geriatric Population and the Increasing Patient Volume for Various Chronic and Age-Related Conditions to Drive Market Growth9.3.4 Italy9.3.4.1 Government Initiatives to Support Market Growth in Italy9.3.5 Spain9.3.5.1 Increasing Adoption of PHM Solutions to Support Market Growth in Spain9.3.6 Rest of Europe9.4 Asia Pacific9.4.1 Japan9.4.1.1 Japan Accounted for the Largest Share of the APAC PHM Market in 20199.4.2 China9.4.2.1 Strong Government Support in China is Driving the PHM Market9.4.3 India9.4.3.1 Growing Volume of Patient Data Generated Within Healthcare Systems to Propel the Market for PHM Solutions in India9.4.4 Rest of Asia Pacific (RoAPAC)9.5 Rest of the World9.5.1 Latin America9.5.1.1 Brazil, Argentina, and Mexico are Emerging Healthcare Markets in Latin America9.5.2 Middle East & Africa9.5.2.1 Increasing Investments in Modernizing Healthcare Systems are Propelling Market Growth

10 Competitive Landscape 10.1 Introduction10.2 Competitive Leadership Mapping (Overall Market)10.2.1 Visionary Leaders10.2.2 Innovators10.2.3 Dynamic Differentiators10.2.4 Emerging Companies10.3 Competitive Scenario

11 Company Profiles 11.1 Cerner Corporation11.2 Epic Systems Corporation11.3 Koninklijke Philips11.4 I2I Population Health11.5 Health Catalyst11.6 Optum (Part of Unitedhealth Group)11.7 Enli Health Intelligence11.8 Eclinicalworks11.9 Allscripts Healthcare Solutions11.1 IBM Corporation11.11 Healthec, LLC11.12 Medecision11.13 Arcadia11.14 Athenahealth11.15 Cotiviti (Verscend Technologies)11.16 Nextgen Healthcare Inc.11.17 Conifer Health Solutions11.18 SPH Analytics11.19 Lightbeam Health Solutions11.20 Innovaccer

For more information about this report visit https://www.researchandmarkets.com/r/q02un0

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/population-health-management-industry-forecast-to-2025-a-39-billion-landscape-opportunity-301027444.html

SOURCE Research and Markets

See more here:
Population Health Management Industry, Forecast to 2025: A $39+ Billion Landscape Opportunity - Yahoo Finance

Verified Market Research recently published a research report titled, Personalized Medicine Market Study Report 2020. The research report is created based on historical and forecast data derived from researchers using primary and secondary methods. The Personalized Medicine market is one of the fastest-growing markets and is expected to witness substantial growth in the forecast years. Reader are provided easy access to thorough analysis on the various aspects such as opportunities and restraints affecting the market. The report clearly explains the trajectory this market will take in the forecast years.

Global Personalized Medicine Market was valued at USD 96.97 Billion in 2018 and is expected to witness a growth of 10.67% from 2019-2026 and reach USD 217.90 Billion by 2026.

Get | Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=7106&utm_source=BCC&utm_medium=002

Personalized Medicine Market Leading Players:

Personalized Medicine Market: Competitive Landscape

This section of the report provides complete information about the various manufacturers in the market. The major manufacturers to which the report refers hold a large proportion that require a microscopic appearance. It provides important information about the different strategies of these manufacturers to combat competition and to expand their presence in the market. In addition, the current trends of the manufacturers are checked in order to innovate their product for the future. This report is intended to help the reader understand the market and make business decisions accordingly.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7106&utm_source=BCC&utm_medium=002

Table of Contents :

Executive Summary: It includes key trends of the Personalized Medicine market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the Personalized Medicine market based on production and revenue.

Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.

Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Personalized Medicine market.

Market Segments: This part of the report discusses about product type and application segments of the Personalized Medicine market based on market share, CAGR, market size, and various other factors.

Research Methodology: This section discusses about the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.

Why to Buy this Report?

The report is a perfect example of a detailed and meticulously prepared research study on the Personalized Medicine market. It can be customized as per the requirements of the client. It not only caters to market players but also stakeholders and key decision makers looking for extensive research and analysis on the Personalized Medicine market.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/global-personalized-medicine-market-size-and-forecast-to-2026/?utm_source=BCC&utm_medium=002

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes; Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: sales@verifiedmarketresearch.com

Tags: Personalized Medicine Market Size, Personalized Medicine Market Trends, Personalized Medicine Market Forecast, Personalized Medicine Market Growth, Personalized Medicine Market Analysis

Read more from the original source:
Personalized Medicine Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - NJ MMA News

This is the first study to demonstrate an overall survival benefit from precision medicine in pancreatic cancer patients.

The study analyzed more than 1,000 pancreatic cancer patients enrolled in PanCAN's Know Your Tumor precision medicine service, powered by Perthera, and found those patients who received matched therapies following molecular profiling of their tumor, using the Perthera Platform, saw an overall survival benefit of one year longer than those who did not.

Pancreatic cancer is the world's toughest cancer with an overall five-year survival rate of just 10 percent. It is currently the third leading cause of cancer-related death in the U.S., underscoring the urgent need for new treatment options and research discoveries in this space.

When PanCAN's Know Your Tumor service was started with Perthera in 2014, key precision medicine resources such as molecular profiling were rarely offered to patients with pancreatic cancer because many doctors assumed there wasn't anything actionable to be found. The study showed that approximately 25 percent of pancreatic cancer patients have an actionable alteration. It also underscores the significance of the most recent National Comprehensive Cancer Network (NCCN) guidelines that state that every patient with pancreatic cancer should get testing - both molecular profiling of their tumor and germline (genetic) testing for alterations they were born with.

The results of this study will help re-write the future for cancer patients for years to come, said Gary Gregory, CEO & President, Perthera, Inc. Increasing patient survival is the cornerstone of the work that PanCAN has spearheaded with Perthera across the U.S. This study clearly proves that, by utilizing precisely matched therapies provided by molecular profiling, along with Therapeutic Intelligence and a Molecular Tumor Board, patients with pancreatic cancer have experienced significant increases in both overall and progression-free survival.

This is critical news for pancreatic cancer patients. Every tumor is different and through this study, we know that patients who get tested and receive treatment based on their tumor's biological characteristics are living longer, said Lynn Matrisian, PhD, MBA, Chief Science Officer at PanCAN and an author on the paper. It is a strong reminder to healthcare professionals to offer tumor profiling to all their pancreatic cancer patients. And it will further provide an incentive to the scientific community to pursue new targeted treatments for even more pancreatic cancer patients.

Several of the molecularly-matched therapies given have now been FDA approved for patients with pancreatic cancer based on select biomarkers. Adopting molecular profiling into routine practice will be critically important to making sure these patients do not miss out on life-extending opportunities that can now be covered by insurance. These real-world outcomes suggest that the adoption of a precision medicine platform can have a substantial impact on survival in patients with pancreatic cancer, and that molecularly-guided treatments targeting oncogenic drivers and the DNA damage repair pathway warrant further prospective evaluation, said Mike Pishvaian, MD, PhD, Perthera's Chief Medical Officer GI Medical Oncology, University of Texas, MD Anderson Cancer Center, Johns Hopkins Medicine.

PanCAN recommends that all pancreatic cancer patients undergo testing of both their tumor tissue (molecular profiling) and blood or saliva for genetic (germline) changes to determine if they have an actionable alteration and to identify treatment options for that patient. Patients can enroll in PanCAN's free Know Your Tumor precision medicine service today, as well as receive free, in-depth, and personalized resources and information on the disease through PanCAN's Patient Central.

The Perthera Platform has been proven to capitalize upon actionable alterations and improve patient outcomes across numerous, peer reviewed clinical publications. The Perthera Platform, which has been used by over 250 cancer treatment sites across the U.S., captures a patient's entire medical and treatment history, as well as their multi-omic molecular profile, to create a personalized treatment plan, that enable physicians to effectively harness the power of precision medicine.

More here:
New Research Reveals Pancreatic Cancer Patients Who Receive Precision Medicine Live An Average Of One Year Longer Than Those Who Do Not #47579 - New...

Artificial Intelligence (AI) is getting increasingly sophisticated day by day in its application, with enhanced efficiency and speed at a lower cost. Every single sector has been reaping benefits from AI in recent times. The Healthcare industry is no exception. Here is decoding the future trajectory of healthcare with AI.

The impact of artificial intelligence in the healthcare industry through machine learning (ML) and natural language processing (NLP) is transforming care delivery. Additionally, patients are expected to gain relatively high access to their health-related information than before through various applications such as smart wearable devices and mobile electronic medical records (EMR).

The personalized healthcare will authorize patients to take the wheel of their well-being, facilitate high-end healthcare, and promote better patient-provider communication to underprivileged areas.

For instance, IBM Watson for Health is helping healthcare organizations to apply cognitive technology to provide a vast amount of power diagnosis and health-related information.

In addition, Googles DeepMind Health is collaborating with researchers, clinicians, and patients in order to solve real-world healthcare problems. Additionally, the company has combined systems neuroscience with machine learning to develop strong general-purpose learning algorithms within neural networks to mimic the human brain.

Companies are working towards developing AI technology to solve several existing challenges, especially within the healthcare space. Strong focus on funding and starting AI healthcare programs played a significant role in Microsoft Corporations decision to launch a 5-year, US$ 40 million program known as AI for Health in January 2019.

The Microsoft program will use artificial intelligence tools to resolve some of the greatest healthcare challenges including global health crises, treatment, and disease diagnosis. Microsoft has also ensured that academia, non-profit, and research organizations have access to this technology, technical experts, and resources to leverage AI for care delivery and research.

In January 2020, these factors influenced Takeda Pharmaceuticals Company and MITs School of Engineering to join hands for three years to drive innovation and application of AI in the healthcare industry and drug development.

AI applications are only centered on three main investment areas: Diagnostics, Engagement, and Digitization. With the rapid advancement in technologies. There are exciting breakthroughs in incorporating AI in medical services.

The most interesting aspect of AI is robots. Robots are not only replacing trained medical staff but also making them more efficient in several areas. Robots help in controlling the cost while potentially providing better care and performing accurate surgery in limited space.

China and the U.S. have started investing in the development of robots to support doctors. In November 2017, a robot in China passed a medical licensing exam using only an AI brain. Also, it was the first-ever semi-automated operating robot that was used to suture blood vessels as fine as 0.03 mm.

In order to prevent coronavirus from spreading, the American doctors are relying on a robot that can measure the patients act and vitals. In addition, robots are also being used for recovery and consulting assistance and transporting units. These robots are showcasing significant potential in revolutionizing medical procedures in the future.

Precision medicine is an emerging approach to disease prevention and treatment. The precision medication approach allows researchers and doctors to predict more accurate treatment and prevention strategies.

The advent of precision medicine technology has allowed healthcare to actively track patients physiology in real-time, take multi-dimensional data, and create predictive algorithms that use collective learnings to calculate individual outcomes.

In recent years, there has been an immense focus on enabling direct-to-consumer genomics. Now, companies are aiming to create patient-centric products within digitization processes and genomics related to ordering complex testing in clinics.

In January 2020, ixLayer, a start-up based in San-Francisco, launched one of its kind precision health testing platforms to enhance the delivery of diagnostic testing and to shorten the complex relationship among physicians, precision health tests, and patients.

Personal health monitoring is a promising example of AI in healthcare. With the emergence of advanced AI and Internet of Medical Things (IoMT), demand for consumer-oriented products such as smart wearables for monitoring well-being is growing significantly.

Owing to the rapid proliferation of smart wearables and mobile apps, enterprises are introducing varied options to monitor personal health.

In October 2019, Gali Health, a health technology company, introduced its Gali AI-powered personal health assistant for people suffering from inflammatory bowel diseases (IBD). It offers health tracking and analytical tools, medically-vetted educational resources, and emotional support to the IBD community.

Similarly, start-ups are also coming forward with innovative devices integrated with state-of-the-art AI technology to contribute to the growing demand for personal health monitoring.

In recent years, AI has been used in numerous ways to support the medical imaging of all kinds. At present, the biggest use for AI is to assist in the analysis of images and perform single narrow recognition tasks.

In the United States, AI is considered highly valuable in enhancing business operations and patients care. It has the greatest impact on patient care by improving the accuracy of clinical outcomes and medical diagnosis.

Strong presence of leading market players in the country is bolstering the demand for medical imaging in hospitals and research centers.

In January 2020, Hitachi Healthcare Americas announced to start a new dedicated R&D center in North America. Medical imaging will leverage the advancements in machine learning and artificial intelligence to bring about next-gen of medical imaging technology.

With a plethora of issues driven by the growing rate of chronic disease and the aging population, the need for new innovative solutions in the healthcare industry is moving on an upswing.

Unleashing AIs complete potential in the healthcare industry is not an easy task. Both healthcare providers and AI developers together will have to tackle all the obstacles on the path towards the integration of new technologies.

Clearing all the hurdles will need a compounding of technological refinement and shifting mindsets. As AI trend become more deep-rooted, it is giving rise to highly ubiquitous discussions. Will AI replace the doctors and medical professionals, especially radiologists and physicians? The answer to this is, it will increase the efficiency of the medical professionals.

Initiatives by IBM Watson and Googles DeepMind will soon unlock the critical answers. However, AI aims to mimic the human brain in healthcare, human judgment, and intuitions that cannot be substituted.

Even though AI is augmenting in existing capabilities of the industry, it is unlikely to fully replace human intervention. AI skilled forces will swap only those who dont want to embrace technology.

Healthcare is a dynamic industry with significant opportunities. However, uncertainty, cost concerns, and complexity are making it an unnerving one.

The best opportunity for healthcare in the near future are hybrid models, where clinicians and physicians will be supported for treatment planning, diagnosis, and identifying risk factors. Also, with an increase in the number of geriatric population and the rise of health-related concerns across the globe, the overall burden of disease management has augmented.

Patients are also expecting better treatment and care. Due to growing innovations in the healthcare industry with respect to improved diagnosis and treatment, AI has gained consideration among the patients and doctors.

In order to develop better medical technology, entrepreneurs, healthcare service providers, investors, policy developers, and patients are coming together.

These factors are set to exhibit a brighter future of AI in the healthcare industry. It is extremely likely that there will be widespread use and massive advancements of AI integrated technology in the next few years. Moreover, healthcare providers are expected to invest in adequate IT infrastructure solutions and data centers to support new technological development.

Healthcare companies should continually integrate new technologies to build strong value and to keep the patients attention.

-

The insights presented in the article are based on a recent research study on Global Artificial Intelligence In Healthcare Market by Future Market Insights.

Abhishek Budholiya is a tech blogger, digital marketing pro, and has contributed to numerous tech magazines. Currently, as a technology and digital branding consultant, he offers his analysis on the tech market research landscape. His forte is analysing the commercial viability of a new breakthrough, a trait you can see in his writing. When he is not ruminating about the tech world, he can be found playing table tennis or hanging out with his friends.

See the original post:
Decoding the Future Trajectory of Healthcare with AI - ReadWrite

Report Scope: The report provides a comprehensive summary of cloud computing for cell biology, genomics and drug design along with detailed profiles of key market players including a revenue product portfolio and recent activities.

New York, March 09, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cloud Computing in Cell Biology, Genomics and Drug Development" - https://www.reportlinker.com/p05873501/?utm_source=GNW The report analyzes trends and dynamics including drivers, limitations, challenges and opportunities.

The report discusses strategies adopted by emerging market players with recommendations for new market entrants.This research study discusses historical, current and potential market size.

The report will help market players and new entrants to make informed decisions about the production and export of goods and services, as well as providing organizations, distributors and exporters information about market development and trends.The study segments the market on the basis of applications and end uses.

A geographical market analysis is provided for all major segments.

Report Includes: - 43 data tables and 18 additional tables - An overview of the global market for cloud computing applications in cell biology, genomics and drug development - Analyses of global and regional market trends, with data from 2018 to 2019, and projections of compound annual growth rates (CAGRs) through 2024 - Assessment of market trends and opportunities, key developments and the impact of cloud computing technology on the biotechnology, pharmaceutical and healthcare industry verticals - Insight into recent developments in cloud infrastructure and information pertaining to key partnerships between cloud service providers and pharma/biotech companies and investment in pharmaceutical R&D sector - Discussion of the suppliers landscape, as well as the market positioning and strategies of key manufacturers and suppliers for cloud computing applications - Review of patent applications filed regarding cloud computing technology in the U.S. healthcare sector - Company profiles of the leading market players, including Amazon Web Services (AWS) Inc., Cisco Systems Inc., DXC Technology, Google LLC, Salesforce.com Inc., and SAP SE

Summary The global market for cloud computing in cell biology, genomics and drug development is estimated to grow at a CAGR of REDACTED during the forecast period.The market was valued at REDACTED in 2018 and is expected to reach REDACTED in 2024.

In biomedical research, cloud computing has resolved big data concerns and improves data, analytics, collaboration and sharing. Increasing biomedical research based on human, animal, plants, and microbes has increased the dependency on proper storage and network infrastructure as well as secure and scalable computing.

With growing big data concerns, researchers are inclined towards cloud computing platforms.These platforms provide flexibility to users to pay according to their usage of cloud services including software, hardware infrastructure and platforms to solve biomedical computation concerns.

The cloud offers ondemand storage and an analysis facility to users which makes it an emerging computing platform to address big data concerns.Owing to the flexibility and cost-effectiveness, cloud services are gaining significant importance in life science research for data storage, communication and collaboration with stakeholders.

On cloud platforms, large datasets and applications for gene sequencing, image analysis, protein folding and data mining can be shared for collaborative research between facilities.

The major pivotal factors contributing to the growth of the market include rising genomics and proteomics research and the increasing number of clinical trials performed across various countries.Considerable public and private investment in genomics and proteomics research is providing support to biotechnology start-ups and research institutes.

This helps healthcare providers to develop and commercialize genomics technologies and personalized medicines. Increasing U.S. FDA approvals for personalized medicines are supporting the growth in genomics research. For example, according to the Personalized Medicine Coalition, in 2018, approximately REDACTED of the REDACTED new molecular entities (NMEs) approved by the FDA are personalized medicines which constitute REDACTED of all new drug approvals. The Coalition classified REDACTED of NMEs as personalized medicines in 2017, REDACTED in 2015 and REDACTED in 2016. The U.S. FDA is making efforts to facilitate access to genomic testing and integration of real-world evidence into its regulatory framework. As a result, the FDA has begun to authorize the marketing of cancer-related genetic tests, and pharmacogenetics were allowed to be sold directly to the consumers. This has resulted in the development of personalized medicine as an emerging practice of medicine that utilizes the genetic profile of an individual to make appropriate decisions regarding prevention, diagnosis and treatment of the condition. Gaining complete knowledge about the patients genetic profile helps doctors to choose proper therapy or medication and to administer it with the proper regimen or dose. Significant data is generated by sequencing a single human genome which necessitates the adoption of cloud services. The 1000 Genomes Project is an effort to sequence genomes of at least a thousand people from across the globe to develop the most comprehensive and medically relevant picture of human genetic variation. This initiative intends to make genomic data easily accessible from international research institutions. Major support for the project is offered by the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), Wellcome Trust Sanger Institute in Hinxton, England and the Beijing Genomics Institute, Shenzhen (BGI Shenzhen) in China.Read the full report: https://www.reportlinker.com/p05873501/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Original post:
Cloud Computing in Cell Biology, Genomics and Drug Development - Yahoo Finance